ProQR Therapeutics reports Q3 cash position of €106.9 million and initiates Phase 1 trial of AX-0810
I'm PortAI, I can summarize articles.
ProQR Therapeutics NV reported a Q3 cash position of €106.9 million, down from €149.4 million at the end of 2024. The company used €39.4 million in operating activities in the first nine months of 2025, with R&D costs rising to €34.8 million. ProQR achieved $2.0 million in milestone payments from Eli Lilly and received CTA authorization for a Phase 1 trial of AX-0810, with initial data expected by year-end. The cash position is projected to last until mid-2027.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments